期刊文献+

再谈糖皮质激素诱导的骨质疏松的诊治 被引量:6

原文传递
导出
摘要 多年来,糖皮质激素在风湿病、肾病、血液病及肿瘤等领域的应用越来越广泛,使多种相关疾病的预后得到明显改善,而长期使用糖皮质激素诱导的骨质疏松(GIOP)越来越受到人们的重视。2001年和2010年美国风湿病学会(ACR)总结了有关GIOP的研究进展,先后两次推出了GIOP诊治共识,之后各国纷纷根据国情制定或修订了共识。
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2013年第6期361-362,共2页 Chinese Journal of Rheumatology
  • 引文网络
  • 相关文献

参考文献13

  • 1Mckenzie R, Reynolds JC, CKFallon A, et al. Decreased bonemineral density during low dose glucocorticoid administration in arandomized, placebo controlled trial. J Rheumatol, 2000 , 27:2222-2226. 被引量:1
  • 2Recommendations for the prevention and glucocorticoid-inducedosteoporosis: 2001 update. American College of RheumatologyAd Hoc Committee on glucocorticoid-induced osteoporosis.Arthritis Rheum, 2001,44: 1496-1503. 被引量:1
  • 3Kaji H, Yamauchi M, Chihara K,et al. The threshold of bonemineral density for vertebral fracture in female patients withglucocorticoid-induced osteoporosis. EndocrJ,2006, 53: 27-34. 被引量:1
  • 4Kanis JA, Johansson H, Oden A, et al. A meta-analysis of priorcorticosteroid use and fracture risk. J Bone Miner Res, 2004,19: 893-899. 被引量:1
  • 5Kanis JA, Oden A, Johansson H,et al. FRAX and its applica-tions to clinical practice. Bone, 2009, 44: 734-743. 被引量:1
  • 6Grossman JM, Gordon R, Ranganath VK, et al. American col-lege of rheumatology 2010 recommendations for the preventionand treatment of glucocorticoid-induced osteoporosis. ArthritisCare Res, 2010,62: 1515-1526. 被引量:1
  • 7张学武.2010年美国风湿病学会最新糖皮质激素诱导的骨质疏松共识备受关注[J].中华风湿病学杂志,2011,15(3):145-146. 被引量:21
  • 8Bischolf-Ferrari HA, Dawson-Hughes B, Staehelin HB,et al.Fall prevention with supplemental and active forms of vitamin D:a meta analysis of randomised controlled trials. Br Med J, 2009,339: b369. 被引量:1
  • 9Black DM,Cummings SR, Karpf D, et al. Randomized trial ofeffect of alendronate on risk of fracture in women with existingvertebral fractures. Lancet, 1996, 348: 1535-1541. 被引量:1
  • 10Delmas PD, Recker RR, Chesnut CH IQ , et al. Daily and inter-mittent oral ibandronate normalize bone turnover and providesignificant reduction in vertebralfracture risk: results from theBONE study. Osteoporos Int, 2004,15: 792-798. 被引量:1

二级参考文献10

  • 1Mckenzie R, Reynolds JC, O'Fallon A, et al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol, 2000, 27: 2222-2226. 被引量:1
  • 2Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid'induced osteaporosis: a meta-analysis. Osteoporos Int, 2002, 13: 777-787. 被引量:1
  • 3Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone, 2006, 39: 253-259. 被引量:1
  • 4American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum, 2001, 44: 1496-503. 被引量:1
  • 5Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior cortieosteroid use and fracture risk. J Bone Miner Res, 2004, 19: 893-899. 被引量:1
  • 6Kanish JA Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone, 2009, 44: 734-743. 被引量:1
  • 7Van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM, 2005, 98: 191-198. 被引量:1
  • 8Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a muhieentre, double-blind, double-dummy, randomised controlled trial. Lancet, 2009, 373: 1253-1263. 被引量:1
  • 9Okada Y, Nawata M, Nakayamada S, et al. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocortieoid therapy. J Rheumatol, 2008, 35: 2249-2254. 被引量:1
  • 10Jennifer MG, Rebecca G, Veena KR, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-Induced osteoporosis. Arthritis Care Res, 2010, 62: 1515-1526. 被引量:1

共引文献24

同被引文献108

  • 1李姝玉,胡大伟.系统性红斑狼疮患者骨质疏松的相关因素[J].中国骨质疏松杂志,2007,13(6):447-450. 被引量:5
  • 2杨瑞红,何权瀛,栗占国.风湿病相关性间质性肺病临床特点及治疗分析[J].中华风湿病学杂志,2007,11(12):736-738. 被引量:9
  • 3Buttgereit FR, Iipworth BJ. Optimised glucocorticoid therapy:the sharpe- ning of an old spear[ J~. Lancet,2005,365 (9461) :801-803. 被引量:1
  • 4Den Uyl DE, Lems WF. Advances in glucocorticoid-induced osteoporosis[J]. Curr Rheumatol Rep ,2011,13 (3) :233-240. 被引量:1
  • 5Stewart PM, Krozowski ZS. 11 beta-hydroxysteroid dehydrogenase [ J 1. Vitam Horm, 1999, 57:249-324. 被引量:1
  • 6Mckay LI, Cidlowski JA.Cross-talk between nuclear factor-kappa B and the steroid hormone receptors : mechanisms of mutual antagonism [ J ]. Mol Endocrinol, 1998,12 ( 1 ) :45-56. 被引量:1
  • 7Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiin- flammatory activity in vivo[ J ]. Mol Endocrinol, 1997, 11 (9) :1245- 1255. 被引量:1
  • 8Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treat- ment of rheumatic diseases: an update on the mechanisms of action [ J ]. Arthritis Rheum ,2004,50 ( 11 ) :3408-3417. 被引量:1
  • 9Aulakh R, Singh S. Strategies for minimizing corticosteroid toxicity: a review [ J 1. Indian J Pediatr,2008,75 (10) : 1067-1073. 被引量:1
  • 10Curtis JR,Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucoeorticoid use [ J ]. Arthritis Rheum ,2006,55 ( 3 ) :420-426. 被引量:1

引证文献6

二级引证文献35

;
使用帮助 返回顶部